Cargando…
The oncolytic peptide LTX-315 triggers immunogenic cell death
LTX-315 is a cationic amphilytic peptide that preferentially permeabilizes mitochondrial membranes, thereby causing partially BAX/BAK1-regulated, caspase-independent necrosis. Based on the observation that intratumorally injected LTX-315 stimulates a strong T lymphocyte-mediated anticancer immune re...
Autores principales: | Zhou, H, Forveille, S, Sauvat, A, Yamazaki, T, Senovilla, L, Ma, Y, Liu, P, Yang, H, Bezu, L, Müller, K, Zitvogel, L, Rekdal, Ø, Kepp, O, Kroemer, G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823948/ https://www.ncbi.nlm.nih.gov/pubmed/26962684 http://dx.doi.org/10.1038/cddis.2016.47 |
Ejemplares similares
-
The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization
por: Zhou, Heng, et al.
Publicado: (2015) -
Anticancer effect obtained against MCA205 sarcoma following treatment with the oncolytic peptide LTX-315 in combination with immune checkpoint inhibitors
por: Rekdal, Öystein, et al.
Publicado: (2015) -
The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells
por: Eike, Liv-Marie, et al.
Publicado: (2015) -
Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model
por: Nestvold, Janne, et al.
Publicado: (2017) -
Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
por: Camilio, Ketil A., et al.
Publicado: (2019)